Oxaliplatin-Based Chemotherapy

Uses

Risks & contraindications

Evidence quality

Highlighted claims

• Oxaliplatin-based doublet chemotherapy is widely used for gastric and gastro-oesophageal junction cancer and is moderately emetogenic. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial
• Eligible trial chemotherapy must be SOX or CAPEOX, with or without PD-1 or PD-L1 inhibitor immunotherapy. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial
• The study's restriction to SOX or CAPEOX limits generalisability to other chemotherapy regimens. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial
• The article says adding immune checkpoint inhibitors to chemotherapy has not been shown to increase CINV risk. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial